Industry News

ImmunoCellular Therapeutics, Ltd. today announced that it plans to report second quarter 2016 financial results on Monday, August 22, 2016. The Company also plans to hold a conference call and webcast on that day at 5:00 pm ET to discuss the second quarter 2016 financial results and provide a business update. The call will be hosted by Andrew Gengos, President and CEO."/>
ImmunoCellular Therapeutics to Report Second Quarter 2016 Financial Results on August 22, 2016
Mesoblast Limited today announced that its intellectual property portfolio covering the use of its Mesenchymal Precursor Cells in the treatment of rheumatic diseases, including rheumatoid arthritis, has been strengthened by the granting of a key patent by the United States Patent and Trademark Office.. The Company’ s patent estate in the US for the treatment of RA and related conditions comprises the newly and recently granted..."/>
Mesoblast Strengthens Key United States Patent Portfolio for the Treatment of Rheumatic Diseases
Anthera Pharmaceuticals reported on Tuesday the election of William Shanahan, MD, JD as its chief medical officer. In the new position, Dr Shanahan will lead the company's blisibimod lupus and Sollpura programmes, with expected topline data in the Q4 of this year: oversee the development of additional indications for blisibimod in IgA nephropathy and cystic fibrosis and for Sollpura in celiac disease and other diseases; As well as work closely with..."/>
Anthera Pharmaceuticals appoints William Shanahan Jr. MD, JD as CMO
Bavarian Nordic A/S announced today its interim financial results for the first half of 2016. Below is a summary of business progress and financial performance for the period. The full interim report is attached as a PDF file and can be found on the company's website,"/>
Bavarian Nordic Announces First Half 2016 Results
CytRx Corporation concerning possible violations of federal securities laws between November 18, 2014 and June 11, 2016 inclusive. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the September 23, 2016 lead plaintiff motion deadline.. To participate in this class action lawsuit, click here."/>
SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against CytRx Corporation and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
Concordia International Corp.. Investors who purchased or otherwise acquired shares between November 12, 2015 and August 12, 2016 inclusive are encouraged to contact the Firm prior to the October 14, 2016 lead plaintiff motion deadline.. If you purchased Concordia shares during the Class Period, please contact Joon M. Khang, Esquire, of Khang& Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine,..."/>
INVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Concordia International Corp. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm
Aetna Inc., the nation's No. 3 health insurer, is pulling the plug on government marketplace plans in Florida and all but four states in 2017, blaming bigger losses than it bargained for. Obamacare foes seized on the retreat as further evidence the health law is "unsustainable," while a top Obama administration official insisted the future of the marketplace remains "strong" as 11 million people have signed up and the uninsured rate has dropped to a record low."/>
Aetna exits 2017 Obamacare plans in Florida, all but 4 states [The Palm Beach Post, Fla.]
Piramal Enterprises Ltd on Tuesday said it has bought Ash Stevens Inc., a US-based contract developer and manufacturer of drugs, in an all-cash deal for $43 million as it seeks to expand its Northern American business. In addition, Piramal will pay a so-called earnout capped at $10 million-- a payment that depends on the business achieving certain financial goals. The purchase, made by a unit of Piramal in the US, is expected to be completed by August end."/>
Piramal Enterprises buys contract drug maker Ash Stevens for $53 million [Mint, New Delhi]
Cardiovascular Systems, Inc., the publicly traded maker of devices to unblock clogged arteries, has appointed a med-tech industry veteran to become its new chief executive. CSI board chairman Scott Ward, 56, was unveiled Tuesday as the new CEO of the company. Ward has been a general partner at Bloomington-based private equity firm SightLine Partners since 2013, and before that he held several senior leadership positions at Medtronic."/>
Cardiovascular Systems names interim CEO Scott Ward to permanent post [Star Tribune (Minneapolis)]
OncoGenex Pharmaceuticals fell more than 40 percent Tuesday after a clinical trial designed to treat cancer did not show favorable results. OncoGenex said its phase 3 trial meant to treat a type of prostate cancer using a drug called custirsen "did not meet the primary endpoint of demonstrating a statistically significant improvement in overall survival" to current treatments on the market. "We are obviously disappointed that custirsen was..."/>
BRIEF: Shares of Bothell biotech tank 40 percent after disappointing clinical results [The Seattle Times]
Perrigo Company plc has agreed to acquire Peachtree City, Georgia-based over-the-counter healthcare and consumer goods products distributor Geiss, Destin and Dunn, Inc., the company said. The transaction is expected to close by the end of August. Perrigo began in 1887 as a packager of generic home remedies and is now a global manufacturer of OTC products and supplier of infant formulas for the store brand market."/>
Perrigo to Acquire Healthcare, Consumer Products Distributor Geiss, Destin and Dunn
Aetna Inc.' s decision to withdraw from Affordable Care Act exchanges in Pennsylvania and 10 other states means that Independence Blue Cross will be the only major firm offering individual plans for 2017 to Southeastern Pennsylvania residents. In its announcement Monday, Aetna, of Hartford, Conn., cited a second-quarter loss of $200 million on the exchange business because a large number of newly insured people needed high-cost care. Aetna serves about 31,000..."/>
Aetna pulls out of ACA exchange in Pa. [The Philadelphia Inquirer]

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary550 Articles
Information Technology459 Articles
Financials400 Articles
Industrials267 Articles
Health Care256 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at